Develops cancer immunotherapies that overcome resistance to checkpoint inhibitors.
Dec 2025Revenue $0.00/yrExpenses $30.1M/yr
Fell below break-even Jul 2024
Figures by year
When will TuHURA Biosciences be profitable again?
Its expenses passed its revenue in Jul 2024. In the 12 months to Dec 2025, revenue was $0.00 and expenses $30.1M.
| Fiscal year to | Revenue | Expenses | Pre-tax profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $30.1M | −$30.1M |
| Dec 2024 | $0.00 | $21.7M | −$21.7M |
| Dec 2023 | $0.00 | −$29.3M | $29.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.